Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading hours on Wednesday. $74.24 million flowed into the stock on the tick-up and $162.32 million flowed out of the stock on the tick-down, for a money net flow of $88.08 million out of the stock. Of all equities tracked, Pfizer had the 10th highest net out-flow for the day. Pfizer traded up $0.22 for the day and closed at $42.33

Several analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Cantor Fitzgerald reiterated a “buy” rating and set a $53.00 price target on shares of Pfizer in a research report on Wednesday, October 17th. ValuEngine upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Tuesday, October 9th. Goldman Sachs Group restated a “neutral” rating and issued a $45.00 target price on shares of Pfizer in a research report on Tuesday, October 30th. Finally, Societe Generale set a $43.00 target price on shares of Pfizer and gave the company a “hold” rating in a research report on Thursday, November 1st. Three research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $44.68.

The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.47. The stock has a market cap of $252.64 billion, a price-to-earnings ratio of 14.11, a P/E/G ratio of 2.43 and a beta of 0.77.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. The firm had revenue of $13.98 billion for the quarter, compared to analyst estimates of $13.92 billion. During the same quarter last year, the business posted $0.62 earnings per share. The company’s quarterly revenue was up 2.0% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.86 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, February 1st will be paid a dividend of $0.36 per share. The ex-dividend date is Thursday, January 31st. This represents a $1.44 annualized dividend and a dividend yield of 3.40%. This is an increase from Pfizer’s previous quarterly dividend of $0.34. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

Pfizer declared that its board has initiated a stock buyback plan on Friday, December 14th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

In related news, EVP Douglas M. Lankler sold 5,000 shares of Pfizer stock in a transaction on Friday, February 1st. The shares were sold at an average price of $42.75, for a total transaction of $213,750.00. Following the completion of the transaction, the executive vice president now owns 83,592 shares of the company’s stock, valued at $3,573,558. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Douglas M. Lankler sold 38,800 shares of Pfizer stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the transaction, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in PFE. Advocacy Wealth Management Services LLC grew its holdings in shares of Pfizer by 48.2% during the fourth quarter. Advocacy Wealth Management Services LLC now owns 793 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 258 shares during the last quarter. Winch Advisory Services LLC grew its holdings in shares of Pfizer by 69.6% during the fourth quarter. Winch Advisory Services LLC now owns 819 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 336 shares during the last quarter. 1 North Wealth Services LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $40,000. Ruggie Capital Group acquired a new position in shares of Pfizer during the fourth quarter valued at about $44,000. Finally, Contravisory Investment Management Inc. grew its holdings in shares of Pfizer by 182.6% during the fourth quarter. Contravisory Investment Management Inc. now owns 1,153 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 745 shares during the last quarter. 69.06% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Traders Sell Pfizer (PFE) on Strength (PFE)” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/traders-sell-pfizer-pfe-on-strength-pfe/2800985.html.

About Pfizer (NYSE:PFE)

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Further Reading: Hedge Funds – Risk or Reward?

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.